LONDON (AFX) - Provexis PLC said it has entered into a long-term collaboration agreement with Unilever PLC to jointly develop a new concentrated format of its patented Fruitflow heart-health technology for application in Unilever's food product portfolio.

Financial details of the deal were not disclosed.

The partners plan to enter into a global licence arrangement for the technology.

Fruitflow is a patented natural extract from tomato which Provexis said has been shown in human trials to reduce the propensity for aberrant blood clotting that is typically associated with cardiovascular disease and which can lead to heart attack or stroke.

In 2005 the market for heart benefit foods was worth 4 bln usd globally, Provexis added.

Considering the growth potential this share has a target of about 8-10p in the medium tern and is a good buy at current levels

As usual, pls do ur own research.

it reads well and the guy is a scottish MEP and the contact numbers are correct ...... however, i fail to see what interest he would have in PXS as food legislation and similar does not appear to be among his interests ...... though i now note that PXS has an R&D lab in Aberdeen, where Fruitflow was first discovered in 1999

cynic
i think you will find that it is during the sleeping period that men get that erection. usually 1/2 to 2/3 of the way through their slumber. could be wrong. seem to recall reading it somewhere once.if concerned or not sure, then an old test once used. NOT by me i must hasten to add, was to wrap a cigar label around "it" to see if it, the cigar label that is, not "it" was broken upon waking thus showing if what is perfectly normal during sleep was or was not happening.
i know that in times gone by if i ever did awaken with an erection that i knew i still had a few hours sleep remaining before having to rise. whoops! i still do, just less aware these days, have forgotten a lot. LoL strange but true.
as always dyor.
regards to all
jkd

try an elastic band, and then boast in the morning that that broke during the night!

cynic
you are so funny and make me laugh, Ta!
regards to you
jkd

I once tried a JCB tyrewe had a large bed.

smutty lot!! concentrate on your shares.

O happy days, O happy days!!!

agreed MP, cynic lowering the tone again and JKD..... WELL at your age.....lol

Blanche I take your comment as a liking for an early riser then.......

MP.it works!I have concentrated on my shares and whooooooooooosh

Works for me.

a bit of a yoyo this morning ..... i suspect there is still some justified suspicion lurking until the actual announcement is made ..... if there are no caveats or similar therein, then maybe a bit more upside in the immediate aftermath

is this going higher

Bit of naughty rumour mongering going on I think. Apparently someone on iii wrote to their MEP to complain about the long EU delay on suitable wording. The reply was approval has been granted the co will be formally notified on 17th and can then make public Friday or Monday. The CEO and the EU official have been getting abusive phone calls --naughty pi s.
I very much doubt that any of it is true but it has certainly perked up the sp!

the big question is whether or not that posting was a fraud ...... my cynical self says yes, for a variety of reasons, though it has indeed taken an inordinate amount of time for this wording approval to be granted

have prudently cut my exposure (at 8.35) as if that post was indeed a fake. then sp will collapse again and not for the first time
if the post is legit, then i shall still make a respectable profit on the balance

worth noting that though volume is quite heavy, it's really not exceptional, implying many are not convinced

L2 makes entertaining viewing
approx 500k bid against 1.7m offered, but there's a complete stand-off on the pricing, with those offering generally wanting 9.5p or more, but no one willing to pay more than 8.3p

cynic is PXS a candidate for "sell on the news"?

definitely!

RNS Number : 2805E
Provexis PLC
17 December 2009






Provexis PLC




("Provexis" or the "Company")




European Commission adoption of claim for Fruitflow




Provexis plc, the life-science business that discovers, develops and licenses scientifically-proven functional food, medical food and dietary supplement technologies, is pleased to announce it has received approval from the European Commission for the use of a health claim for its Fruitflow anti-thrombotic technology.




The European Commission has informed the Company that its decision authorising the new health claim, the first to be approved under Article 13(5), will be adopted today and will be published in the Official Journal of the EU in the coming days. This is the final stage of the process to substantiate the claim that Fruitflow, the water-soluble tomato concentrate, "helps maintain normal platelet aggregation, which contributes to healthy blood flow". The Company understands that flexibility will be allowed in the use of the claim wording in consumer communication and as such will enable "contributes to healthy blood flow" to be highlighted as the key consumer message. The Commission decision to authorise the use of the wording "helps maintain normal platelet aggregation, which contributes to healthy blood flow" will assist the Company in its negotiations with commercial partners for Fruitflow.




The European Commission's decision was made under Regulation (EC) No 1924/2006 on nutrition and health claims. This was following the approval in May 2009 of Fruitflow as the first technology to have a health claim approved by the European Food Safety Authority ("EFSA") under Article 13(5) of the Regulation for proprietary and emerging science. Under Article 13(5), Provexis has proprietary rights over the majority of the scientific studies substantiating this claim for a period of five years. This is in addition to the extensive patent coverage in place.




Stephen Moon, CEO of Provexis said:




"We are delighted with the Commission's decision which affirms Fruitflow as a scientifically and commercially credible product which is proven to contribute to healthy blood flow. The conclusion of this process marks the first adoption of a nutrition and health claim under Article 13(5) in Europe. This is a significant landmark, not only for our own company and the development of Fruitflow, but for British food technology and the industry as a whole.




We are excited about the next stage as we continue to explore options to make this technology available via consumer products in partnership with global brand owners and ingredients manufacturers."




-ends-




For further information please contact:




Stephen Moon, Chief Executive

Provexis plc Tel: 01753 752290




Sam Plumptre/Bobbie Hilliam Tel: 020 7071 4317

Evolution Securities




Notes to Editors




About Fruitflow




Provexis' development of Fruitflow, a water-soluble tomato concentrate, is a breakthrough in anti-thrombotic food technology. In human trials, consumption of the Fruitflow extract has been proven to reduce platelet aggregation in 97% of subjects. The effect takes place within three hours of consumption and lasts for up to eighteen hours, making it ideal for daily dosage in functional foods or dietary supplements. Provexis has developed a syrup format for use in food & beverages and a concentrated powder format for tablets and capsules.




Fruitflow syrup is GRAS (Generally Regarded as Safe) by the US FDA and is not regarded as a Novel Food in the EU, clearing it for wide use in foods, beverages and supplements. In May 2009, the Fruitflow technology was the first to be substantiated by the European Food Safety Authority ("EFSA") under the new Article 13(5) for proprietary and emerging science.




The technology has been granted patents in the EU, US, Australia, Canada and Mexico, with Japan pending. Further patents have been filed for the bioactive components of Fruitflow and for other developmental areas such as deep vein thrombosis and triglyceride lowering.




About Provexis plc




AIM-listed Provexis is focused on the discovery, development and licensing of technologies for the functional food, dietary supplement and medical food sectors.




The company was originally spun out of the Rowett Institute (now part of the University of Aberdeen) in 1999 to commercialise their tomato extract discovery using venture capital funding. Provexis Limited was reversed into Nutrinnovator in 2005 and its major investors are DSM Venturing (22.6%) and Rising Stars Growth Fund (part of Enterprise Ventures) (11.2%).




The company has additional biotechnology developments, including a joint venture with the University of Liverpool to develop an extract of plantain which aids the treatment of inflammatory bowel disease, and an early stage technology under option from University of Manchester for the prevention and treatment of peptic ulcers.


This information is provided by RNS
The company news service from the London Stock Exchange

END


MSCCKOKKFBDKOBD

Credit Cards
Find the lowest APR's from over 300 cards Savings
The best rates from over 1079 savings accounts Mortgages
Compare over 7000 mortgages Life Assurance
Select the best from over 100 policies
| Register | Our Services | About MoneyAM | Terms and Conditions | Privacy Policy | Investment Warning | Content Standards | Corporate Solutions | Advertise With Us |
2006 MoneyAM

W H O O P E E ! !